Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers

Autoimmun Rev. 2017 Jan;16(1):16-21. doi: 10.1016/j.autrev.2016.09.016. Epub 2016 Sep 21.

Abstract

Macrophage activation syndrome (MAS) is a rare, life-threatening disease in which early diagnosis and aggressive therapeutic strategy may improve the outcome. Due to its rarity, epidemiologic data are still lacking. Hyperferritinemia is frequently associated with MAS and might modulate the cytokine storm, which is involved in the development of multiple organ failure. In this paper, we investigated clinical data, treatments, and outcome of a homogeneous cohort of 41 adult MAS patients, complicating autoimmune rheumatic diseases. MAS-related death occurred in 17 patients (42.5%) during the follow-up, and older age and increased serum ferritin levels, at the time of diagnosis, were significantly associated with mortality. In conclusion, adult MAS is associated with high mortality rate. Some clinical features at diagnosis may be predictive of MAS-associated death.

Keywords: Adult onset Still's disease; Hyperferritinemic syndrome; Macrophage activation syndrome.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Ambulatory Care Facilities
  • Autoimmune Diseases / diagnosis*
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / mortality
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Macrophage Activation Syndrome / diagnosis*
  • Macrophage Activation Syndrome / drug therapy
  • Macrophage Activation Syndrome / mortality
  • Male
  • Middle Aged
  • Prognosis
  • Retrospective Studies
  • Treatment Outcome

Substances

  • Immunosuppressive Agents